ALI HEALTH Surges Over 6% in Morning Trading as Analysts Expect Company to Benefit from Strong Demand for Innovative Drugs

Deep News

昨天

ALI HEALTH (00241) surged 6.63% in morning trading, currently trading at HK$6.92 with a turnover of HK$1.193 billion.

HSBC Global Research noted that health products are expected to continue being ALI HEALTH's fastest-growing category, benefiting from its robust platform ecosystem. Regarding pharmaceuticals, while the company's continued focus on first-party sales (1P) profitability may limit sales growth, the firm believes that as social insurance claims tighten and offline traffic shifts online, ALI HEALTH will benefit from strong demand for innovative drugs. Combined with strong advertising momentum, HSBC has raised its revenue growth forecast for ALI HEALTH's fiscal year 2026 from the previous 9% year-over-year to 15% year-over-year. Profit margins are expected to improve due to the revenue structure shifting toward non-pharmaceutical products and enhanced 1P profit margins, with the company's fiscal year 2026 net profit growth potentially exceeding revenue growth.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1126765801"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1126765801\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1126765801?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-09 12:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126765801","market":"sh","top_or_hot":-1,"title":"ALI HEALTH Surges Over 6% in Morning Trading as Analysts Expect Company to Benefit from Strong Demand for Innovative Drugs","media":"Deep News","content":"<p>ALI HEALTH (00241) surged 6.63% in morning trading, currently trading at HK$6.92 with a turnover of HK$1.193 billion.</p>\n<p>HSBC Global Research noted that health products are expected to continue being ALI HEALTH's fastest-growing category, benefiting from its robust platform ecosystem. Regarding pharmaceuticals, while the company's continued focus on first-party sales (1P) profitability may limit sales growth, the firm believes that as social insurance claims tighten and offline traffic shifts online, ALI HEALTH will benefit from strong demand for innovative drugs. Combined with strong advertising momentum, HSBC has raised its revenue growth forecast for ALI HEALTH's fiscal year 2026 from the previous 9% year-over-year to 15% year-over-year. Profit margins are expected to improve due to the revenue structure shifting toward non-pharmaceutical products and enhanced 1P profit margins, with the company's fiscal year 2026 net profit growth potentially exceeding revenue growth.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ALI HEALTH Surges Over 6% in Morning Trading as Analysts Expect Company to Benefit from Strong Demand for Innovative Drugs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nALI HEALTH Surges Over 6% in Morning Trading as Analysts Expect Company to Benefit from Strong Demand for Innovative Drugs\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time smaller\">2025-09-09 12:20</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>ALI HEALTH (00241) surged 6.63% in morning trading, currently trading at HK$6.92 with a turnover of HK$1.193 billion.</p>\n<p>HSBC Global Research noted that health products are expected to continue being ALI HEALTH's fastest-growing category, benefiting from its robust platform ecosystem. Regarding pharmaceuticals, while the company's continued focus on first-party sales (1P) profitability may limit sales growth, the firm believes that as social insurance claims tighten and offline traffic shifts online, ALI HEALTH will benefit from strong demand for innovative drugs. Combined with strong advertising momentum, HSBC has raised its revenue growth forecast for ALI HEALTH's fiscal year 2026 from the previous 9% year-over-year to 15% year-over-year. Profit margins are expected to improve due to the revenue structure shifting toward non-pharmaceutical products and enhanced 1P profit margins, with the company's fiscal year 2026 net profit growth potentially exceeding revenue growth.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1142","symbol_name":"互聯網與直銷零售","start_time":0,"source_url":"","article_id":"1126765801","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126765801","pubTimestamp":1757391650,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"ALI HEALTH (00241) surged 6.63% in morning trading, currently trading at HK$6.92 with a turnover of HK$1.193 billion. HSBC Global Research noted that health products are expected to continue being...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1142":"互联网与直销零售","BK1502":"双十一","BK1591":"就地过年概念","BK1615":"港股-互联网","BK1189":"医疗保健技术","BK1247":"药品零售","BK1584":"蚂蚁金服概念","BK1501":"阿里概念股","BK1571":"互联网医疗","BK1617":"AI医疗","00241":"阿里健康","BK1589":"北水核心资产","BK1515":"抗疫概念","BK1610":"ETF&股票定投概念"},"translate_title":"阿里健康早盘大涨超6%分析师预计公司将受益于创新药强劲需求","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00241":1},"content_text":"ALI HEALTH (00241) surged 6.63% in morning trading, currently trading at HK$6.92 with a turnover of HK$1.193 billion.\nHSBC Global Research noted that health products are expected to continue being ALI HEALTH's fastest-growing category, benefiting from its robust platform ecosystem. Regarding pharmaceuticals, while the company's continued focus on first-party sales (1P) profitability may limit sales growth, the firm believes that as social insurance claims tighten and offline traffic shifts online, ALI HEALTH will benefit from strong demand for innovative drugs. Combined with strong advertising momentum, HSBC has raised its revenue growth forecast for ALI HEALTH's fiscal year 2026 from the previous 9% year-over-year to 15% year-over-year. Profit margins are expected to improve due to the revenue structure shifting toward non-pharmaceutical products and enhanced 1P profit margins, with the company's fiscal year 2026 net profit growth potentially exceeding revenue growth.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}